Berkeley HeartLabs Suffers Another Down Quarter as Volumes Shrivel

Q2 receipts fell 22 percent, testing volume shrank 23 percent, and Celera cut its companywide 2010 revenue outlook by 6.6 percent due to "reimbursement practices, … the healthcare system generally, and competitive pressures."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.